viruslik
particl
vlp
hold
tremend
potenti
vaccin
candid
innov
biopharmaceut
present
remark
advantag
close
mimick
threedimension
natur
actual
viru
lack
viru
genom
packag
insid
capsid
result
equal
effici
safer
prophylaxi
anticip
compar
inactiv
live
attenu
viral
vaccin
advent
success
case
approv
vlpbase
vaccin
pharmaceut
compani
inde
redirect
resourc
develop
product
paper
review
current
choic
trend
largescal
product
purif
vlpbase
vaccin
gener
baculoviru
express
vector
system
use
insect
cell
viruslik
particl
vlp
multimer
protein
complex
mimick
organ
conform
nativ
virus
lack
viral
genom
potenti
permit
safer
vaccin
candid
vlp
fall
size
rang
virus
nm
case
exact
size
morpholog
depend
particular
viral
protein
incorpor
vlp
offer
promis
approach
product
vaccin
mani
diseas
repetit
high
densiti
display
epitop
potenti
highli
effect
elicit
strong
immun
respons
bachmann
et
al
vlp
therefor
constitut
safe
effect
approach
induct
neutral
antibodi
surfac
protein
solubl
form
protein
subunit
fail
vlp
also
exploit
platform
present
foreign
epitop
andor
target
molecul
chimer
vlp
achiev
modif
vlp
gene
sequenc
fusion
vlp
protein
foreign
vaccin
protein
assembl
vlp
de
novo
synthesi
vlp
chimera
extens
explor
vaccin
candid
last
year
pumpen
gren
vlp
gener
base
singl
protein
commerci
avail
vlpbase
human
vaccin
glaxosmithklin
gsk
human
papillomaviru
hepat
b
viru
merck
co
recombivax
hepat
b
viru
human
papillomaviru
envisag
success
current
larg
number
vlpbase
vaccin
candid
includ
vlp
compos
multipl
differ
protein
especi
differ
viral
structur
protein
need
stabl
vlp
either
clinic
trial
undergo
preclin
evalu
exampl
includ
influenza
viru
parvoviru
norwalk
variou
chimer
vlp
clinicaltrialsgov
ad
viral
protein
bring
nevertheless
extra
challeng
set
optim
process
paramet
upand
downstream
furthermor
requir
qualiti
control
method
inevit
complex
mixtur
assembl
nonassembl
protein
coexist
issu
address
depth
follow
section
order
deliv
product
suffici
amount
evalu
costeffect
clinic
trial
eventu
widespread
use
robust
scalabl
manufactur
strategi
need
put
place
even
proofofconcept
demonstr
support
strong
preclin
data
vlpbase
product
candid
could
never
competit
market
manufactur
process
scalabl
costeffect
buckland
requir
strong
product
develop
effort
modern
molecular
biolog
technolog
permit
greater
flexibl
design
singl
unit
multisubunit
chimer
type
vlp
base
target
nativ
virus
express
system
use
grgacic
anderson
baculoviru
express
vector
bev
insect
cell
ic
system
constitut
express
system
choic
purpos
system
versatil
multipl
recombin
baculovirus
contain
requir
gene
interest
product
differ
viral
protein
multicistron
vector
differ
promotersenhanc
use
infect
insect
cell
eg
spodoptera
frugiperda
express
larg
amount
requir
viral
protein
assembl
multimer
unit
correspond
vlp
current
one
vlpbase
product
licens
human
recombin
protein
biopharmaceut
produc
use
bevsic
gsk
cervarix
human
papillomaviru
vlp
cancer
vaccin
preclin
develop
sever
vlp
produc
via
bevsic
eg
ebola
vlp
sun
et
al
hantaan
viru
betenbaugh
et
al
hepat
c
viru
hcv
vlp
lechmann
et
al
herp
simplex
viru
vlp
tatman
et
al
noroviru
vlp
almanza
et
al
other
et
al
tabl
summar
differ
vlp
produc
use
bevsic
long
track
record
recombin
protein
product
largescal
suspens
cultur
establish
either
stir
rock
bioreactor
bevsic
shown
one
best
cell
cultur
system
purpos
potenti
disadvantag
bevsic
resid
pattern
posttransl
modif
davi
wood
insect
cell
perform
simpler
posttransl
glycosyl
base
enrich
mannos
comparison
mammalian
cell
shortcom
certain
applic
wu
et
al
nevertheless
improv
insect
cell
line
human
cell
perform
mammalianlik
posttransl
modif
becom
avail
hang
et
al
see
also
van
oer
volum
thu
insect
cell
glycosyl
pattern
biolog
function
desir
vlp
match
bevsic
like
strongest
candid
tool
vlpbase
vaccin
develop
bioprocess
challeng
associ
largescal
product
purif
vlpbase
vaccin
discuss
review
depend
specif
target
vlp
vaccin
name
biolog
function
differ
express
system
employ
express
requir
subunit
bacteria
yeast
mammalian
cell
plant
cell
insect
cell
use
although
system
advantag
drawback
primari
focu
within
context
special
issu
insect
virus
medicin
insect
cell
system
use
recombin
baculovirus
major
tool
extens
analysi
differ
express
system
avail
elsewher
et
al
insect
cell
fast
specif
growth
rate
serum
andor
proteinfre
medium
cultur
addit
cell
perfectli
adapt
suspens
condit
allow
largescal
upstream
process
usp
oreilli
et
al
run
batch
fedbatch
bioreactor
l
straightforward
cell
densiti
usual
reach
high
level
cell
ml
gener
robust
long
cultur
condit
tightli
monitor
control
latter
featur
make
bev
ic
especi
attract
compar
mammalian
express
system
often
requir
tediou
cell
cultur
adapt
procedur
suspens
insect
cell
also
abl
grow
absenc
serum
highli
desir
serum
may
caus
adventiti
virus
therebi
requir
intens
purif
process
order
remov
serum
protein
addit
host
cell
impur
bevsic
system
character
twophas
process
insect
cell
grown
desir
viabl
cell
densiti
ii
infect
recombin
baculovirus
protein
express
exponenti
cell
growth
phase
oppos
system
second
step
involv
definit
suitabl
multipl
infect
moi
time
infect
toi
cell
concentr
infect
cci
design
product
recombin
baculovirus
carri
desir
gene
interest
typic
fast
allow
short
turnaround
time
critic
produc
vaccin
base
virus
whose
surfac
protein
rapidli
mutat
differ
season
eg
influenza
viru
cox
hashimoto
product
develop
flexibl
essenti
time
respons
potenti
pandem
outbreak
one
import
product
issu
upstream
process
usp
yield
dramat
determin
scale
need
vlp
yield
vari
mgl
hundr
mgl
tabl
although
express
system
like
bacteria
yeast
normal
achiev
higher
yield
would
match
degre
complex
vlp
design
bevsic
five
theoret
even
divers
protein
possibl
high
express
level
explain
abil
viru
shut
transcript
host
gene
alloc
cellular
transcript
translat
machineri
overexpress
heterolog
gene
deliv
upon
infect
roldao
et
al
specif
influenza
viru
bevsicderiv
influenza
vlp
provid
good
match
wildtyp
influenza
strain
robinson
moreov
product
yield
significantli
higher
compar
eggor
mammalian
cellbas
vlp
product
one
order
magnitud
higher
term
hemagglutinin
ha
titer
furthermor
product
process
shorten
approxim
week
identif
new
strain
contrast
week
need
tradit
eggbas
manufactur
process
robinson
singleus
bioreactor
emerg
strong
altern
stainlesssteel
vessel
ozturk
hu
usp
technolog
present
mani
benefit
includ
singleor
campaignus
thu
elimin
crosscontamin
ii
clean
steril
cost
iii
residu
valid
cost
iv
increas
flexibl
process
scale
adjust
v
lower
upfront
invest
stainlesssteel
reactor
vi
short
turnaround
time
vii
eas
instal
littl
facil
space
util
still
drawback
go
fulli
dispos
exampl
limit
extract
andor
leachabl
substanc
qualiti
control
data
dispos
materi
dispos
manufactur
ii
dispos
bag
system
difficult
handl
scale
l
iii
pressur
limit
iv
high
temperatur
limit
nonetheless
current
improv
usp
yield
case
earli
proofofconcept
stage
small
medium
scale
suffici
make
dispos
bioreactor
extrem
appeal
addit
given
lead
biopharmaceut
gener
much
smoother
technolog
transfer
contract
manufactur
organ
cmo
reli
dispos
manufactur
stainlesssteel
equip
due
flexibl
allow
former
provid
suspens
cultur
fast
specif
cell
growth
rate
demonstr
envirom
insect
cell
host
examin
identifi
impact
differ
paramet
upon
recombin
baculoviru
replic
viral
protein
express
ozturk
hu
et
al
includ
bioreactor
paramet
dissolv
oxygen
concentr
ph
temperatur
agit
rate
inlet
ga
flow
composit
volum
fluid
dynam
paramet
may
influenc
vlp
product
interf
cell
growth
metabol
activ
even
protein
posttransl
modif
biolog
process
complex
highli
interact
respond
greater
lesser
extent
environment
stimuli
although
insect
cell
robust
optim
bioreactor
paramet
care
perform
tabl
highlight
critic
step
design
optim
usp
regard
molecularcel
biolog
natur
promot
strongli
impact
product
earli
late
late
promot
chosen
earli
promot
induc
lower
yield
result
fact
earli
stage
enzym
transcript
factor
necessari
protein
express
yet
fulli
activ
roldao
et
al
late
late
promot
protein
express
occur
toward
end
viral
replic
cycl
cell
approach
stationari
death
phase
proteas
may
start
degrad
newli
produc
protein
posttransl
modif
moi
ie
averag
number
virus
per
infect
cell
time
harvest
toh
cci
strongli
influenc
protein
express
consequ
vlp
assembl
optim
moi
typic
depend
target
product
singl
multipl
protein
base
vlp
product
strategi
singleor
coinfect
singl
protein
express
low
moi
viruscel
normal
induc
higher
volumetr
product
high
moi
viruscel
outcom
higher
infect
cell
concentr
specif
product
low
high
moi
compar
et
al
theori
differ
volumetr
product
could
counterbalanc
increas
cci
howev
problem
may
aris
eg
observ
cell
densiti
effect
affect
cellspecif
product
increas
cci
bernal
et
al
although
fedbatch
perfus
cultur
mode
least
theoret
improv
specif
product
within
wide
rang
moi
often
neither
practic
econom
attract
metabolomeproteom
recent
fluxom
teixeira
et
al
tool
show
great
promis
usp
optim
integr
analysi
metabol
flux
deriv
onlin
process
control
strategi
improv
product
yield
product
achiev
novel
system
biolog
tool
eg
metabol
flux
analysi
coupl
mathemat
model
analyz
complex
network
metabolit
flux
identifi
limit
factor
teixeira
et
al
regard
assembl
requir
protein
subunit
final
vlp
thermodynam
studi
prove
use
identifi
suit
environment
condit
upon
product
also
stabil
mainten
downstream
process
dsp
storag
recent
studi
vitro
assembl
disassembl
rotaviru
vlp
explor
physicochem
paramet
affect
assembl
stabil
produc
vlp
mellado
et
al
protein
macrostructur
stabil
shown
highli
depend
ph
ionic
strength
temperatur
followup
team
develop
thermodynam
equilibriumbas
model
describ
first
time
assembl
triplelay
vlp
et
al
simul
suggest
concentr
correctli
assembl
particl
maxim
structur
protein
provid
exact
stoichiometr
ratio
high
concentr
insight
lead
conclus
amount
unassembledmalform
vlp
typic
observ
mani
system
like
due
nonoptim
ratio
protein
moment
assembl
insid
cell
host
order
use
vlp
vaccin
efficaci
safeti
essenti
henc
puriti
potenc
consist
becom
crucial
develop
largescal
bioprocess
high
yield
short
process
time
reduc
total
cost
scalabl
robustnessi
thu
critic
largescal
vlp
manufactur
clear
trend
observ
laboratori
purif
method
like
sucros
cesium
chlorid
gradient
ultracentrifug
procedur
toward
scalabl
process
like
tangenti
flow
filtrat
chromatographi
morenweis
ultracentrifugationbas
procedur
nonscal
tediou
labor
intens
howev
procedur
still
use
order
prepar
standard
serv
refer
materi
process
develop
first
downstream
process
dsp
step
depend
whether
vlp
releas
extracellular
medium
vlp
effici
secret
cell
lysi
extract
step
might
requir
actual
clarif
step
fig
howev
current
trend
design
clone
compat
effici
secretori
pathway
facilit
shorten
dsp
natur
tendenc
singl
protein
adopt
incorrect
equal
stabl
macroassembl
structur
pose
seriou
concern
dsp
control
process
condit
eg
salt
dival
ion
concentr
ph
crucial
avoid
random
protein
aggreg
challeng
case
strategi
develop
take
account
process
es
capabl
differenti
productderiv
impur
singl
macroassembl
deriv
actual
vlp
besid
processderiv
impur
primarili
hostcel
protein
hostcel
dna
baculovirus
one
critic
drawback
bevsic
coproduct
recombin
baculovirus
envelop
virus
infect
process
baculovirus
shown
adjuv
activ
remov
inactiv
might
induc
neg
synergist
effect
target
vlpbase
immunolog
respons
hervasstubb
et
al
obvious
complic
dsp
recombin
baculovirus
vlp
size
within
order
magnitud
biophys
featur
electrostat
need
exploit
allow
separ
two
viru
particl
may
prove
challeng
vlp
also
envelop
eg
influenza
vlp
wu
et
al
last
resort
purifi
vlp
undergo
chemic
inactiv
treatment
elimin
possibl
baculoviru
infect
rueda
et
al
given
particular
challeng
characterist
design
vlp
final
clinic
applic
necessari
simplifi
downstream
process
much
possibl
furthermor
critic
issu
associ
vlp
product
system
overcom
earlier
process
possibl
eg
product
degrad
due
proteolyt
activ
diminish
stabil
due
lack
given
structur
protein
upon
design
vlp
overal
downstream
process
design
accommod
best
compromis
cost
throughput
puriti
need
meet
desir
puriti
potenc
capac
integr
dsp
includ
deliveri
product
larg
quantiti
scalabl
high
qualiti
puriti
high
titer
potenc
costeffect
manner
intensif
process
utmost
import
one
devis
strategi
later
effici
transfer
product
site
oper
current
good
manufactur
practic
cgmp
exampl
fit
concept
includ
filtrat
depthfilt
clarif
step
tangentialflow
ultrafiltrationdiafiltr
concentrationstep
affin
ionexchang
chromatographi
capturepurif
step
final
sizeexclus
type
chromatographi
final
polish
step
typic
process
repres
fig
case
rotaviru
vlp
peixoto
et
al
clarif
step
design
effici
remov
cell
debri
larg
aggreg
maintain
protect
qualiti
product
clarif
process
especi
bevsic
due
presenc
host
cell
deriv
proteas
gotoh
et
al
antiproteolyt
preserv
need
bioreact
initi
dsp
avoid
extend
degrad
extern
glycoprotein
layer
essenti
final
applic
gold
standard
industri
clarif
centrifug
cell
sediment
either
continu
batch
peixoto
et
al
note
inclus
lysi
step
help
releas
vlp
cell
host
reproduc
peixoto
et
al
recent
howev
membran
process
appear
attract
altern
scalabl
guarante
membran
area
easili
scale
stack
membran
unit
parallel
exampl
deadend
dispos
depthfilt
use
effici
peixoto
et
al
tangenti
flow
microfiltr
use
membran
cassett
hollow
fiber
unit
saha
et
al
lm
retent
pore
also
possibl
use
depth
filter
make
siev
particul
retent
process
much
effici
depthdepend
size
separ
factor
moreov
due
charg
natur
depthfilt
materi
nonpropylen
threedimension
arrang
prashad
tarrach
higher
degre
cell
cell
debri
retent
achiev
vlp
still
permeat
care
select
depthfilt
materi
critic
use
noninert
materi
may
bind
effici
debri
also
vlp
siev
tabl
line
increas
interest
use
cleaningand
validationfre
dispos
technolog
membran
process
repres
clear
advantag
centrifug
former
easili
adapt
dispos
format
inde
varieti
choic
dsp
equip
manufactur
membran
process
perform
fairli
well
recoveri
yield
frequent
peixoto
et
al
vicent
et
al
concentr
critic
step
ubiquit
dsp
vlp
stream
volum
reduc
earli
dsp
possibl
order
reduc
upfront
invest
equip
downstream
overal
consum
buffer
ultrafiltr
diafiltr
use
tangenti
flow
mode
process
choic
see
fig
exampl
adsorpt
chromatographi
oper
bindelut
mode
constitut
good
altern
concentrationpurif
step
chromatographi
oper
captur
step
stage
good
concentr
factor
achiev
upon
elut
product
dilut
bulk
capac
chosen
matrix
signific
vlp
question
recurr
option
kalbfuss
et
al
vicent
et
al
recent
chromatograph
matric
base
porou
membran
layer
monolith
drawn
attent
dsp
engin
porou
matric
particularli
suit
larg
particl
vlp
specif
surfac
area
per
unit
volum
porou
matric
pore
size
lm
mustang
membran
adsorb
pall
lm
sartobind
membran
adsorb
sartoriusstedim
biotech
lm
cim
monolith
bia
separ
significantli
larger
resin
bead
use
packedb
chromatographi
whose
pore
gener
nm
convent
resin
nm
perfus
resin
triliski
et
al
vlp
rang
nm
nm
hinder
bind
onto
intern
surfac
area
resin
result
suboptim
usag
matric
addit
due
porou
natur
matric
diffusion
mass
transfer
resist
highli
reduc
case
vlp
rather
small
diffus
coeffici
compar
smaller
biolog
protein
matric
clearli
present
advantag
packedb
chromatographi
moreov
porou
matric
purchas
dispos
unit
elimin
clean
steril
well
valid
cost
chromatograph
chemistri
effici
use
includ
hydrophob
interact
vedvick
et
al
hydroxyapatit
cook
sulfat
wolff
et
al
ligand
latter
two
consid
pseudo
affin
chromatographi
ligand
order
select
best
matrix
best
oper
condit
highthroughput
screen
design
experi
doe
approach
implement
use
scaledown
model
tabl
team
focus
ionexchang
iex
chromatographi
develop
scaledown
model
base
dynam
light
scatter
surfac
plasmon
reson
address
electrostat
properti
viral
particl
use
insight
optim
ionexchang
chromatograph
step
vicent
et
al
b
polish
critic
step
clinic
grade
materi
envisag
residu
hostcel
protein
hostcel
dna
need
remov
accept
threshold
valu
typic
lgdose
ngdose
dna
fragment
exceed
bp
respect
cber
guidelin
bevsic
use
product
vlp
one
need
devis
suitabl
strategi
remov
least
recombin
baculovirus
may
challeng
especi
case
vlp
similar
size
andor
overal
surfac
charg
given
ph
affin
ionexchang
chromatograph
process
principl
suit
polish
allow
high
resolut
separ
morenweis
iex
chromatographi
constitut
process
choic
remov
flowthrough
pool
hostcel
protein
hostcel
dna
kalbfuss
et
al
vicent
et
al
wu
et
al
howev
vlp
vlpderiv
impur
nonassembl
protein
macrostructur
electrostat
properti
sizeexclus
chromatographi
sec
probabl
becom
better
altern
differ
size
still
signific
polish
vlp
pool
obtain
void
volum
gel
filtrat
column
peixoto
et
al
ultrafiltrationdiafiltr
ufdf
usual
tangenti
flow
filtrat
constitut
altern
latest
stage
remov
lower
molecular
weight
impur
ufdf
sec
effici
allow
exchang
final
formul
buffer
tangenti
flow
filtrat
scale
easili
sec
alway
limit
process
scale
chromatographi
column
volum
load
exceed
column
bed
volum
biopharmaceut
process
steril
filtrat
typic
final
step
vial
even
though
vlp
gener
smaller
nm
depend
vlp
biophys
properti
low
adsorptioninert
steril
membran
materi
evalu
order
minim
product
loss
due
nonspecif
bind
analyt
play
crucial
limit
role
develop
vlpbase
vaccin
complex
biopharmaceut
upon
usp
dsp
develop
one
must
cogniz
mani
featur
requir
effect
biolog
use
vlp
typic
good
percentag
vlp
protein
perhap
even
properli
assembl
desir
vlp
et
al
therefor
critic
qualit
quantit
analyt
method
develop
critic
process
develop
design
less
blindli
usp
optim
eg
chang
strategi
infect
select
right
chromatograph
matrixoper
condit
eg
remov
specificresili
impur
moreov
cgmp
process
product
ident
qualiti
titer
puriti
consistencyreproduc
need
care
document
tabl
show
basic
set
method
need
ensur
manufactur
qualiti
consist
particular
inprocess
control
vitro
potenc
ident
assay
well
method
estim
major
processderiv
impur
hostcel
protein
host
cell
dna
residu
baculovirus
fundament
rather
extens
wishlist
shown
tabl
stress
challeng
complex
underli
manufactur
complex
biopharmaceut
thu
clear
product
process
understand
streamlin
optim
overal
manufactur
strategi
converg
guidelin
qualiti
designprocess
analyt
technolog
approach
fda
mollerup
et
al
morenweis
eas
product
releas
clinic
trial
vlpbase
vaccin
candid
produc
mean
bevsic
receiv
wider
attent
success
case
human
papillomaviru
vlp
commerci
remark
versatil
baculovirus
host
insect
cell
slowli
step
world
market
medicin
mani
product
test
preclin
clinic
trial
clear
still
mani
bioprocess
challeng
ahead
often
product
yield
unsatisfactori
downstream
process
adequ
address
high
recoveri
yield
productivitypur
newer
tool
system
biolog
complet
set
analyt
conjunct
innov
purif
develop
strategi
determin
pace
novel
vlpbase
vaccin
candid
abbrevi
bca
bicinchonin
acid
bv
recombin
baculovirus
cze
capillari
zone
electrophoresi
dl
dynam
light
scatter
elisa
enzymelink
immunosorb
assay
hcp
hostcel
protein
rtqpcr
realtim
quantit
pcr
sem
scan
electron
microscopi
spr
surfac
plasmon
reson
srid
singl
radial
immunodiffus
tem
transmiss
electron
microscopi
